|
1
|
Piepoli MF, Hoes AW, Agewall S, Albus C,
Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et
al: 2016 European Guidelines on cardiovascular disease prevention
in clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of
10 societies and by invited experts)Developed with the special
contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). Eur Heart J. 37:2315–2381.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mauricio MD, Aldasoro M, Ortega J and Vila
JM: Endothelial dysfunction in morbid obesity. Curr Pharm Des.
19:5718–5729. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vanhoutte PM, Shimokawa H, Tang EH and
Feletou M: Endothelial dysfunction and vascular disease. Acta
Physiol (Oxf). 196:193–222. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Molinaro R, Boada C, Del Rosal GM, Hartman
KA, Corbo C, Andrews ED, Toledano-Furman NE, Cooke JP and Tasciotti
E: Vascular inflammation: A novel access route for nanomedicine.
Methodist Debakey Cardiovasc J. 12:169–174. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Seneviratne AN and Monaco C: Role of
inflammatory cells and toll-like receptors in atherosclerosis. Curr
Vasc Pharmacol. 13:146–160. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hansson GK: Inflammation, atherosclerosis,
and coronary artery disease. N Engl J Med. 352:1685–1695.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Packard CJ: LDL cholesterol: How low to
go? Trends Cardiovasc Med. 28:348–354. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bäck M and Hansson GK: Anti-inflammatory
therapies for atherosclerosis. Nat Rev Cardiol. 12:199–211.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Childs KS and Goodbourn S: Identification
of novel co-repressor molecules for interferon regulatory factor-2.
Nucleic Acids Res. 31:3016–3026. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Carneiro FR, Ramalho-Oliveira R, Mognol GP
and Viola JP: Interferon regulatory factor 2 binding protein 2 is a
new NFAT1 partner and represses its transcriptional activity. Mol
Cell Biol. 31:2889–2901. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Stadhouders R, Cico A, Stephen T,
Thongjuea S, Kolovos P, Baymaz HI, Yu X, Demmers J, Bezstarosti K,
Maas A, et al: Control of developmentally primed erythroid genes by
combinatorial co-repressor actions. Nat Commun.
6(8893)2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li T, Luo Q, He L, Li D, Li Q, Wang C, Xie
J and Yi C: Interferon regulatory factor-2 binding protein 2
ameliorates sepsis-induced cardiomyopathy via AMPK-mediated
anti-inflammation and anti-apoptosis. Inflammation. 43:1464–1475.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ma YL, Xia JL and Gao X: Suppressing
Irf2bp2 expressions accelerates metabolic syndrome-associated brain
injury and hepatic dyslipidemia. Biochem Biophys Res Commun.
503:1651–1658. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen HH, Keyhanian K, Zhou X, Vilmundarson
RO, Almontashiri NA, Cruz SA, Pandey NR, Lerma Yap N, Ho T, Stewart
CA, et al: IRF2BP2 reduces macrophage inflammation and
susceptibility to atherosclerosis. Circ Res. 117:671–683.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jha P and Das H: KLF2 in regulation of
NF-κB-mediated immune cell function and inflammation. Int J Mol
Sci. 18(2383)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhou Z, Tang AT, Wong WY, Bamezai S,
Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, et al:
Cerebral cavernous malformations arise from endothelial gain of
MEKK3-KLF2/4 signalling. Nature. 532:122–126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wu W, Geng P, Zhu J, Li JW, Zhang L, Chen
WL, Zhang DF, Lu Y and Xu XH: KLF2 regulates eNOS uncoupling via
Nrf2/HO-1 in endothelial cells under hypoxia and reoxygenation.
Chem Biol Interact. 305:105–111. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Das H, Kumar A, Lin Z, Patino WD, Hwang
PM, Feinberg MW, Majumder PK and Jain MK: Kruppel-like factor 2
(KLF2) regulates proinflammatory activation of monocytes. Proc Natl
Acad Sci USA. 103:6653–6658. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhuang T, Liu J, Chen X, Zhang L, Pi J,
Sun H, Li L, Bauer R, Wang H, Yu Z, et al: Endothelial Foxp1
suppresses atherosclerosis via modulation of Nlrp3 inflammasome
activation. Circ Res. 125:590–605. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhao D, Sun X, Lv S, Sun M, Guo H, Zhai Y,
Wang Z, Dai P, Zheng L, Ye M and Wang X: Salidroside attenuates
oxidized low-density lipoprotein-induced endothelial cell injury
via promotion of the AMPK/SIRT1 pathway. Int J Mol Med.
43:2279–2290. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lee WJ, Ou HC, Hsu WC, Chou MM, Tseng JJ,
Hsu SL, Tsai KL and Sheu WHH: Ellagic acid inhibits oxidized
LDL-mediated LOX-1 expression, ROS generation, and inflammation in
human endothelial cells. J Vasc Surg. 52:1290–1300. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li H, Zhao Q, Chang L, Wei C, Bei H, Yin
Y, Chen M, Wang H, Liang J and Wu Y: LncRNA MALAT1 modulates ox-LDL
induced EndMT through the Wnt/β-catenin signaling pathway. Lipids
Health Dis. 18(62)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen
M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW and Milstone
DS: A major role for VCAM-1, but not ICAM-1, in early
atherosclerosis. J Clin Invest. 107:1255–1262. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Galkina E and Ley K: Vascular adhesion
molecules in atherosclerosis. Arterioscler Thromb Vasc Biol.
27:2292–2301. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang PL: Endothelial nitric oxide
synthase and endothelial dysfunction. Curr Hypertens Rep.
5:473–480. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lyons D: Impairment and restoration of
nitric oxide-dependent vasodilation in cardiovascular disease. Int
J Cardiol. 62 (Suppl 2):S101–S109. 1997.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Skuratovskaia D, Vulf M, Komar A,
Kirienkova E and Litvinova L: Promising directions in
atherosclerosis treatment based on epigenetic regulation using
MicroRNAs and long noncoding RNAs. Biomolecules.
9(226)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhao Y, Evans MA, Allison MA, Bertoni AG,
Budoff MJ, Criqui MH, Malik S, Ouyang P, Polak JF and Wong ND:
Multisite atherosclerosis in subjects with metabolic syndrome and
diabetes and relation to cardiovascular events: The multi-ethnic
study of atherosclerosis. Atherosclerosis. 282:202–209.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gimbrone MA Jr and García-Cardeña G:
Endothelial cell dysfunction and the pathobiology of
atherosclerosis. Circ Res. 118:620–636. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang Y, Mu Q, Zhou Z, Song H, Zhang Y, Wu
F, Jiang M, Wang F, Zhang W, Li L, et al: Protective effect of
irisin on atherosclerosis via suppressing oxidized low density
lipoprotein induced vascular inflammation and endothelial
dysfunction. PLoS One. 11(e0158038)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang H, Mohamed AS and Zhou SH: Oxidized
low density lipoprotein, stem cells, and atherosclerosis. Lipids
Health Dis. 11(85)2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen PY, Qin L, Baeyens N, Li G, Afolabi
T, Budatha M, Tellides G, Schwartz MA and Simons M:
Endothelial-to-mesenchymal transition drives atherosclerosis
progression. J Clin Invest. 125:4514–4528. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Kim I, Kim JH, Kim K, Seong S and Kim N:
The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast
differentiation. BMB Rep. 52:469–474. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Atkins GB, Wang Y, Mahabeleshwar GH, Shi
H, Gao H, Kawanami D, Natesan V, Lin Z, Simon DI and Jain MK:
Hemizygous deficiency of Krüppel-like factor 2 augments
experimental atherosclerosis. Circ Res. 103:690–693.
2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Xu Y, Liu P, Xu S, Koroleva M, Zhang S, Si
S and Jin ZG: Tannic acid as a plant-derived polyphenol exerts
vasoprotection via enhancing KLF2 expression in endothelial cells.
Sci Rep. 7(6686)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Novodvorsky P and Chico TJ: The role of
the transcription factor KLF2 in vascular development and disease.
Prog Mol Biol Transl Sci. 124:155–188. 2014.PubMed/NCBI View Article : Google Scholar
|
